LANDMARK OUTCOMES STUDY SHOWS THAT REPATHA (EVOLOCUMAB) DECREASES LDL-C TO UNPRECEDENTED LOW LEVELS AND REDUCES RISK OF CARDIOVASCULAR EVENTS WITH NO NEW SAFETY ISSUES
Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, maximally reducing low-density lipoprotein cholesterol levels with Repatha, beyond what is possible with the current best therapy alone, leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations.